RESTLESS LEGS SYNDROME AND INSOMNIA FREQUENCY IN XXXX WITH PSORIASIS.

@entity1 @entity1569 @entity4531 @entity25 @entity22
BACKGROUND: To assess the prevalence and severity of @entity4531 in @entity1569 @entity1 and to investigate its effects on sleep and quality of life. METHODS: Seventy @entity1 with @entity1569 in Trakya University Medical Faculty Dermatology Department and also applied to Neurology Department in the same center and 70 volunteer controls were enrolled in the study. Severity of the @entity4531 ( @entity4531 ) was determined using International @entity4531 Study Group (IRLSSG) criteria among the @entity1 who have been diagnosed with @entity4531 based on IRLSSG criteria. The presence of @entity22 in @entity1 was detected using International Classification of @entity25 (ICSD-II) criteria. Additionally, to evaluate the severity of the disease and quality of life, Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) tests were applied to the @entity1 with @entity1569 . RESULTS: @entity4531 frequency in @entity1 with @entity1569 was 28 (40%) compared to the control group 10 (14.2%), and the difference was statistically significant (p<0.001). IRLSSG severity scores were higher in @entity1 with @entity1569 who had @entity22 secondary to @entity4531 compared to those who did not have @entity22 (p<0.001). The mean values of PASI were 7.54 +/- 6.52 in the presence of @entity22 and 3.27 +/- 2.69 in the absence of @entity22 . The difference was statistically significant (p<0.001). No significant difference was found in DLQI scores between @entity1 with @entity4531 and without @entity4531 or between @entity1 with and without @entity22 (p>0.05). DISCUSSIONS: @entity4531 frequency in @entity1 with @entity1569 was significantly higher than in the control group. In addition, we found that @entity4531 is more common but @entity4531 severity was mildly high in @entity1 with @entity1569 relative to controls. However, there was a correlation between the increase in severity of @entity4531 with secondary @entity22 @entity1 who were diagnosed with @entity4531 . It may be beneficial to consider @entity4531 and @entity22 for each @entity1 diagnosed with @entity1569 .
